AI Article Synopsis
- Assisted reproduction technologies, especially in vitro fertilization (IVF), have progressed significantly since the birth of the first IVF baby, with innovations in IVF labs being crucial for improving success rates.
- A key development in IVF history is the introduction of conventional ovarian stimulation, which plays a vital role in the treatment process.
- This review highlights treatment milestones and ongoing innovations, aims to provide practical insights for physicians, and emphasizes the importance of tailoring treatments to individual patient needs.
Article Abstract
Assisted reproduction technologies have substantially advanced since the birth of the first in vitro fertilization baby, and innovations within in vitro fertilization laboratories have been of paramount importance for the overall assisted reproduction technology success rates. However, one of the milestones in the history of in vitro fertilization is irrefutably the introduction of conventional ovarian stimulation. The objective of the present review is to provide an update on conventional ovarian stimulation, by giving an overview of treatment milestones, together with the latest innovations currently being investigated. The realization of an assisted reproduction technology treatment depends on many steps that can be medically manipulated and must be harmoniously combined, starting from the follicular phase and ending with luteal phase support. New technologies in the pharmaceutical sector are fundamental to optimize efficiency and tailor treatment approaches to individual needs. The present review aims to offer physicians a useful summary of the more recent publications and to facilitate the translation of research findings into daily clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40265-020-01324-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The first multiple center prospective study of rhFSH CTP in patients undergoing assisted reproductive technology in China.
Sci Rep
January 2025
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.
We assessed the safety and efficacy of rhFSH-CTP, a novel long-acting FSH agent, in controlled ovarian hyperstimulation for patients undergoing ART. A multi-center, open-label, randomized, positive-control, non-inferiority clinical trial was conducted. The study consisted of a phase III randomized design, with a 1:1 ratio favoring the rhFSH-CTP group over the control group.
View Article and Find Full Text PDFEnhanced Ovarian FKBP51 Expression is Associated with Ovarian Aging: A Molecular Insight for Age-Related Fertility in Women.
F S Sci
January 2025
Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA. Electronic address:
Objective: To study the relationship between FK506-binding protein 51 (FKBP51) and ovarian aging and/or diminished ovarian reserve (DOR) in human ovaries by comparing FKBP51 levels in granulosa (GC) and cumulus cells (CC), collected during controlled ovarian stimulation (COS) from women of advanced reproductive age and/or with a diagnosis of DOR with that of young women with normal ovarian reserve. To explore the association between increased FKBP51 expression and human ovarian aging further, expression of FKBP51 was compared in ovarian stroma of post-menopausal versus pre-menopausal women. Lastly, this relation was further queried by comparing ovarian expression of several collagen genes as markers of ovarian fibrosis in 14-month-old wild type (Fkbp5) and Fkbp5 knockout (Fkbp5) mice.
View Article and Find Full Text PDFHighly purified-hMG versus rFSH in ovarian hyperstimulation in women undergoing elective fertility preservation: a retrospective cohort study.
JBRA Assist Reprod
January 2025
Racine IVF Unit, Fertility Institute, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel affiliated to the Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Objective: To compare recombinant FSH (rFSH) with highly purified-human menopausal gonadotrophin (hp-hMG) on ovarian response in women undergoing elective fertility preservation (FP).
Methods: This retrospective study included 456 women who underwent elective FP with gonadotropin-releasing hormone (GnRH) antagonist or progestin-primed ovarian stimulation (PPOS) protocols between 01/2017-12/2021. Only the first treatment cycle of each woman was included.
Embryo Cryopreservation: What do couples think about it?
JBRA Assist Reprod
January 2025
Department of Gynecology and Obstetrics, Ribeirão Preto Medical School of University of Sao Paulo, Ribeirão Preto, Brazil.
Objective: To investigate the perspectives of infertile couples regarding embryo cryopreservation throughout assisted reproduction treatment.
Methods: The convenience sample included infertile couples undergoing assisted reproduction treatment. They responded to a questionnaire specifically designed to gauge views and opinions on cryopreservation of surplus embryos.
Heterotopic Triplet Pregnancy After Assisted Reproductive Techniques: A Systematic Review.
Cureus
December 2024
Department of Obstetrics and Gynecology, School of Health Sciences, University of Patras, Patras, GRC.
Heterotopic pregnancy is defined as the simultaneous presence of an intrauterine and an extrauterine pregnancy and is considered a rare condition. As a part of this entity, heterotopic triplet pregnancy, defined as the presence of three embryos, with at least one being ectopic, is exceedingly rare. In recent years, the broad use of assisted reproductive techniques to help infertile couples has contributed to the constant rise of non-spontaneous heterotopic triplets.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!